The cumulative lifetime risk of ovarian cancer in the general female population is estimated at 1.3%, increasing up to 36–53% and 10–25% by the age 70 in BRCA1 and BRCA2 mutation carriers, respectively [8,43,44,45], but it is basically unknown for the remaining majority of patients diagnosed with breast cancer who do not carry any pathogenetic BRCA variant. This evidence concerns the gene BRCA2 and ovarian cancer.